Unprecedented advances have been made in cancer treatment with the use of immune
checkpoint blockade (ICB). However, responses are limited to a subset of patients, and …

Mucosal vaccines offer the potential to trigger robust protective immune responses at the
predominant sites of pathogen infection. In principle, the induction of adaptive immunity at …

Activation of the innate immune STimulator of INterferon Genes (STING) pathway potentiates
antitumour immunity, but systemic delivery of STING agonists to tumours is challenging. We …

Therapeutic cancer vaccines have undergone a resurgence in the past decade. A better
understanding of the breadth of tumour-associated antigens, the native immune response …

Immunotherapy has revolutionized cancer treatment, but efficacy remains limited in most
clinical settings. Cancer is a systemic disease that induces many functional and …

Immune checkpoint blockade, which blocks inhibitory signals of T cell activation, has shown
tremendous success in treating cancer, although success still remains limited to a fraction of …

For many solid malignancies, lymph node (LN) involvement represents a harbinger of
distant metastatic disease and, therefore, an important prognostic factor. Beyond its utility as …

Dendritic cells (DCs) exhibit a specialized antigen-presenting function and play crucial roles
in both innate and adaptive immune responses. Due to their ability to cross-present tumor …

Tumor-infiltrating dendritic cells (DCs) assume varied functional states that impact anti-tumor
immunity. To delineate the DC states associated with productive anti-tumor T cell immunity …

T cell immunoglobulin and mucin-containing molecule 3 (TIM-3), first identified as a
molecule expressed on interferon-γ producing T cells, is emerging as an important immune …